Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|December 2, 2022
Daily Dose: ASCVD Risk Reduced by 10% with Diet
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On December 1, 2022, we reported on an analysis of the original landmark Dietary Approaches to Stop Hypertension (DASH) trial published in the American Journal of Cardiology.
The study
Researchers evaluated the effects of 3 dietary approaches on 10-year risk of atherosclerotic cardiovascular disease (ASCVD) based on blood pressure and lipid measurements made before and after the intervention period of 8 weeks. The dietary approaches were a typical “Western” diet (control; low in fiber, high in fat and sodium), a diet heavy in fruit and vegetables, or the DASH diet, which encouraged high intake of fruits, vegetables, and low-fat dairy products, and had a favorable macronutrient profile.
Investigators found that adherence to the DASH diet vs the control diet during the trial was associated with a -10.3% (95% CI, -14.4 to -5.9) reduction in 10-year ASCVD risk. Findings were similar when they compared the results of following the control diet with following the fruits and vegetables diet with the latter associated with a -9.9% (95% CI, -14.0 to -5.5) reduction in 10-year ASCVD risk score. The impact of both regimens, the team observed, was greater among women and Black adults in the cohort.
Clinical implications
"Our study suggests that the DASH dietary pattern may offer Black adults more prevention benefits than the emphasis on fruits and vegetables alone. This is particularly relevant as dietary pattern has been identified as one of the most important mediators of hypertension risk among Black adults."
Click here for more details.
Advertisement
Related to this article
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
Advertisement
Advertisement
Trending on Patient Care Online
1
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
2
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
3
New Study Finds Low Initiation, Persistence With Menopause Hormone Therapy
4
Primary Care Lens: Atrial Fibrillation From Detection to Referral in Primary Care
5